[{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Secnidazole","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Granule","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Secnidazole","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Granule","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Secnidazole","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Granule","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Hetero Drugs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tedizolid","moa":"50S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Hetero Drugs","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hetero Drugs \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hetero Drugs \/ Inapplicable"},{"orgOrder":0,"company":"Wockhardt","sponsor":"Jiangxi Jemincare Group Company","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2021","type":"Partnership","leadProduct":"Nafithromycin","moa":"50S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Wockhardt","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Wockhardt \/ Jiangxi Jemincare Group Company","highestDevelopmentStatusID":"10","companyTruncated":"Wockhardt \/ Jiangxi Jemincare Group Company"},{"orgOrder":0,"company":"Cadila Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Mycobacterium w","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cadila Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Cadila Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cadila Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"VPM1002","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Serum Institute of India \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Serum Institute of India \/ Inapplicable"},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"HDT Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"HGCO19","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gennova Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Gennova Biopharmaceuticals \/ HDT Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Gennova Biopharmaceuticals \/ HDT Biotech"},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"HGCO19","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gennova Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Gennova Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gennova Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"HGCO19","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gennova Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Gennova Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gennova Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"HGCO19","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gennova Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Gennova Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gennova Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Wockhardt","sponsor":"UK Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Wockhardt","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Wockhardt \/ UK Government","highestDevelopmentStatusID":"10","companyTruncated":"Wockhardt \/ UK Government"},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"HGCO19","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gennova Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Gennova Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gennova Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"HGCO19","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gennova Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Gennova Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gennova Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"HGCO19","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gennova Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Gennova Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gennova Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Wockhardt","sponsor":"US Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Wockhardt","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Wockhardt \/ US Government","highestDevelopmentStatusID":"10","companyTruncated":"Wockhardt \/ US Government"},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"HGCO19","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gennova Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Gennova Biopharmaceuticals \/ CEPI","highestDevelopmentStatusID":"10","companyTruncated":"Gennova Biopharmaceuticals \/ CEPI"},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"HDT Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"HGCO19","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gennova Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Gennova Biopharmaceuticals \/ HDT Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Gennova Biopharmaceuticals \/ HDT Biotech"},{"orgOrder":0,"company":"Hetero Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Hetero Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Hetero Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hetero Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Biological E","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biological E","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Biological E \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Biological E \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Hetero Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Hetero Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Hetero Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hetero Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Jubilant Generics","sponsor":"Novavax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Partnership","leadProduct":"Matrix-m1","moa":"||SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Jubilant Generics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Jubilant Generics \/ Novavax","highestDevelopmentStatusID":"10","companyTruncated":"Jubilant Generics \/ Novavax"},{"orgOrder":0,"company":"Biophore India Pharmaceuticals Pvt Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biophore India Pharmaceuticals Pvt Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biophore India Pharmaceuticals Pvt Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biophore India Pharmaceuticals Pvt Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Cipla","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cipla \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cipla \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"MSN Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"MSN Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MSN Laboratories \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MSN Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Optimus Pharma","sponsor":"JSS Medical Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Optimus Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Optimus Pharma \/ JSS Medical Research","highestDevelopmentStatusID":"10","companyTruncated":"Optimus Pharma \/ JSS Medical Research"},{"orgOrder":0,"company":"Hempstreet","sponsor":"MGC Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Curcumin","moa":"||PPA-gamma receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Hempstreet","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Hempstreet \/ MGC Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Hempstreet \/ MGC Pharmaceuticals"},{"orgOrder":0,"company":"Supriya Lifescience","sponsor":"Revive Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Supriya Lifescience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Supriya Lifescience \/ Revive Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Supriya Lifescience \/ Revive Therapeutics"},{"orgOrder":0,"company":"LAXAI Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"||RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"LAXAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"LAXAI Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"LAXAI Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"NovaLead Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"PFOR","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"NovaLead Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NovaLead Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NovaLead Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Bharat Serums & Vaccines ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Urinastatin","moa":"Serine protease","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bharat Serums & Vaccines ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bharat Serums & Vaccines ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bharat Serums & Vaccines ltd \/ Inapplicable"},{"orgOrder":0,"company":"NovaLead Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NLP21","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"NovaLead Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NovaLead Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NovaLead Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Panacea Biotec Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Tetravalent Chimeric Dengue Vaccine Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Panacea Biotec Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Panacea Biotec Limited \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Panacea Biotec Limited \/ Inapplicable"},{"orgOrder":0,"company":"Panacea Biotec Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Tetravalent Chimeric Dengue Vaccine Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Panacea Biotec Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Panacea Biotec Limited \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Panacea Biotec Limited \/ Inapplicable"},{"orgOrder":0,"company":"Panacea Biotec Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Tetravalent Chimeric Dengue Vaccine Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Panacea Biotec Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Panacea Biotec Limited \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Panacea Biotec Limited \/ Inapplicable"},{"orgOrder":0,"company":"Aurigene Pharmaceutical Services","sponsor":"The Global Antibiotic Research and Development Partnership","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Zoliflodacin","moa":"||DNA gyrase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aurigene Pharmaceutical Services","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Aurigene Pharmaceutical Services \/ The Global Antibiotic Research and Development Partnership","highestDevelopmentStatusID":"10","companyTruncated":"Aurigene Pharmaceutical Services \/ The Global Antibiotic Research and Development Partnership"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"The Global Antibiotic Research and Development Partnership","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Zoliflodacin","moa":"||DNA gyrase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Dr. Reddy\\'s Laboratories \/ The Global Antibiotic Research and Development Partnership","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\'s Laboratories \/ The Global Antibiotic Research and Development Partnership"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Inactivated Trivalent Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Tergene Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Pneumococcal 15-Valent Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Tergene Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Tergene Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tergene Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Biofabri","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Mycobacterium Tuberculosis Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Bharat Biotech \/ Biofabri","highestDevelopmentStatusID":"10","companyTruncated":"Bharat Biotech \/ Biofabri"},{"orgOrder":0,"company":"Wockhardt","sponsor":"ICICI Prudential","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2024","type":"Private Placement","leadProduct":"Cefepime","moa":"||Cell wall peptidoglycan synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Wockhardt","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Wockhardt \/ ICICI Prudential","highestDevelopmentStatusID":"10","companyTruncated":"Wockhardt \/ ICICI Prudential"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
